Newron's Evenamide Advances with Targeted Mechanism and Secure Funding

Newron presents new data for Evenamide, a schizophrenia drug targeting the hippocampus. Phase III trial on track for 2026 results, backed by €38M funding and extended loan maturity.

Italian biopharmaceutical company Newron SpA recently showcased promising new data for its lead candidate, Evenamide, at the SIRS congress in Florence. The presentation highlighted a key differentiator for the potential schizophrenia therapy: its activity targets the hippocampus, a brain region where conventional antipsychotic medications demonstrate limited efficacy. This positions Evenamide to address a significant unmet need, as current second-generation treatments primarily alleviate positive symptoms while often leaving cognitive and negative symptoms unresolved.

Clinical Development Progresses as Planned

The drug's pivotal Phase III trial, designated ENIGMA-TRS-2 (NCT07184619), is advancing according to schedule. This randomized, double-blind, placebo-controlled study is evaluating a twice-daily 15 mg dose in 400 patients. The primary endpoint for the registration program is the change from baseline in the PANSS score after a twelve-week treatment period. Top-line results from this crucial study are anticipated in the fourth quarter of 2026, setting the stage for potential regulatory submissions to both the U.S. FDA and the European EMA.

Strengthened Financial Position and Board Updates

Newron's financial footing appears solid, providing runway for its clinical programs. An early 2026 capital raise successfully secured up to €38 million. Furthermore, the company has reached an agreement with the European Investment Bank to extend the maturity of existing loan facilities to June 2028. These combined resources are intended to fund operations and the completion of the Phase III development plan through 2027.

Governance has also seen recent developments. Dr. Chris Martin assumed the role of Chairman following the Annual General Meeting in April 2025. The agenda for the upcoming AGM on April 23 includes the election of two new independent board members, George Garibaldi and Paolo Zocchi, alongside the formal approval of the 2025 financial statements.